Americas · General news · Toronto Star
Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial–mesenchymal transition…
Read the full article on Toronto Star Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.thestar.com)




